This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Avadel Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 1/4
Şu anda CEO hakkında yeterli bilgiye sahip değiliz.
Anahtar bilgiler
İcra Kurulu Başkanı
n/a
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | no data |
| CEO sahipliği | n/a |
| Yönetim ortalama görev süresi | 5.2yrs |
| Yönetim Kurulu ortalama görev süresi | Veri yok |
Son yönetim güncellemeleri
Recent updates
AVDL: Revised Acquisition Terms And CVR Structure Will Shape Future Risk Balance
Analysts lifted their price target on Avadel Pharmaceuticals to $22.50 from $20, citing improved acquisition terms and updated deal expectations as the key reasons for the change. Analyst Commentary Recent research highlights how the evolving acquisition proposals around Avadel Pharmaceuticals are shaping valuation views and risk assessments for investors following the stock.
AVDL: Alkermes Cash Deal And CVR Structure Will Define Limited Upside
Analysts lifted their fair value estimate for Avadel Pharmaceuticals to $18.50 from $16.00, citing updated acquisition terms, improved contingent value right economics, and revised assumptions around margins and future P/E multiples following recent Street research. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has shifted toward a more balanced and, in several cases, more cautious stance as the Alkermes acquisition framework has taken shape.
AVDL: Cash Deal Terms And CVR Outcome Will Shape Future Returns
Analysts kept their fair value estimate for Avadel Pharmaceuticals at $23.00 per share while adjusting key assumptions, citing the updated Alkermes and Lundbeck proposals and evolving views on Lumryz royalties and contingent value right terms as the main drivers of the new target range around recent Street marks near $20.00 to $22.50. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has centered on the competing acquisition proposals from Alkermes and Lundbeck, as well as the value of Lumryz royalties and the contingent value right, or CVR, tied to potential future approvals.AVDL: Cash Deal And Contingent Payout Will Shape Future Returns
Analysts have trimmed their price target on Avadel Pharmaceuticals to $23.00 from about $31.47, reflecting updated assumptions for slightly higher risk, stronger revenue growth, and sharply improved profitability metrics in light of the evolving Alkermes acquisition dynamics and Lumryz-driven cash flow profile. Analyst Commentary Across recent research notes, bullish analysts acknowledge that headline price targets for Avadel are now clustered in the high teens to low twenties, reflecting the proposed acquisition by Alkermes and the embedded value of the contingent value right tied to Lumryz milestones.AVDL: Acquisition And CVR Milestones Will Define Balanced Risk Reward Profile
Analysts have nudged our fair value estimate for Avadel Pharmaceuticals slightly lower, from $21.06 to $20.94 per share, as they balance modestly reduced long term multiple assumptions with the evolving acquisition landscape and contingent value right dynamics highlighted in recent research. Analyst Commentary Street research reflects a more balanced, wait and see stance on Avadel as the Alkermes transaction and competing interest from Lundbeck reshape the risk reward profile.AVDL: Competing Acquisition Proposals Will Shape Outcomes Amid Industry Uncertainty
Analysts have raised their fair value estimate for Avadel Pharmaceuticals from $19.13 to $21.06 per share. They cite improving profit margins and stronger near-term acquisition prospects as key factors behind the upward revision.AVDL: Future Acquisition to Reshape Sleep Disorder Market Amid Shifting Competitive Risks
Analysts have lowered their price target for Avadel Pharmaceuticals from $20.90 to $19.13 per share. This change reflects recent acquisition agreements and shifting perspectives on the company’s long-term growth prospects.Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Oct 23Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised their price target for Avadel Pharmaceuticals from $20.30 to $20.90, citing continued commercial momentum for Lumryz. However, they note this optimism is tempered by competitive and market uncertainties.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts marginally raised Avadel Pharmaceuticals’ price target to $20.30, citing strong commercial execution and growing Lumryz adoption, while noting competitive risks may limit upside. Analyst Commentary Bullish analysts highlight that commercial investments are delivering tangible benefits, evidenced by improved persistency and an expanding number of reimbursed Lumryz patients.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted. Analyst Commentary Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.Rising Awareness Of Sleep Disorders Will Drive Future Demand
The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Aug 02Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jun 10
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
May 04Avadel Pharmaceuticals: Moving To A Speculative Buy
Feb 11The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Feb 07Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jan 13The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22CEO
Avadel Pharmaceuticals CEO'su yok ya da onlar hakkında elimizde veri yok.
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Senior VP | 6.2yrs | US$2.29m | 0.089% $ 1.9m | |
| General Counsel | 5.4yrs | US$2.04m | 0.0090% $ 190.3k | |
| Chief Operating Officer | less than a year | Veri yok | Veri yok | |
| VP of Corporate and Business Development | 10.6yrs | Veri yok | 0.17% $ 3.7m | |
| Vice President of People & Culture | 4.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Technical Operations | 6.2yrs | Veri yok | Veri yok | |
| Senior Vice President of Medical & Clinical Affairs | 5.2yrs | Veri yok | Veri yok | |
| Chief Business Officer | 1.8yrs | Veri yok | Veri yok | |
| Senior Vice President of Regulatory & Quality | 1.8yrs | Veri yok | Veri yok |
5.2yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: AVDL 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/02/14 04:14 |
| Gün Sonu Hisse Fiyatı | 2026/02/11 00:00 |
| Kazançlar | 2025/09/30 |
| Yıllık Kazançlar | 2024/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Avadel Pharmaceuticals plc 8 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |